Literature DB >> 18076375

Applying small RNA molecules to the directed treatment of human diseases: realizing the potential.

Todd C Pappas1, Andreas G Bader, Bernard F Andruss, David Brown, Lance P Ford.   

Abstract

Small interfering RNAs (siRNA) and microRNAs (miRNA) are gaining considerable attention in the pharmaceutical and biotechnology industries, as research has revealed their likely clinical and agricultural applications. The capacity of siRNAs to dramatically and specifically reduce the expression of targeted genes has spawned multiple clinical trials to establish the therapeutic potential of small RNAs targeting viral, cancer and other disease-related genes. The successful application of siRNAs will enable the development of therapeutic applications based on miRNAs that have been observed to contribute to a variety of human diseases. This article reviews advances that have been made to apply small RNAs as therapeutics.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18076375     DOI： 10.1517/14728222.12.1.115

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN： 1472-8222            Impact factor:   6.902


  10 in total

Review 1.  miRNAs: effectors of environmental influences on gene expression and disease.

Authors:  Alice Hudder; Raymond F Novak
Journal:  Toxicol Sci       Date:  2008-02-16       Impact factor: 4.849

Review 2.  RNA surveillance: molecular approaches in transcript quality control and their implications in clinical diseases.

Authors:  Karen C M Moraes
Journal:  Mol Med       Date:  2009-10-07       Impact factor: 6.354

3.  The effect of proteoglycans inhibited by RNA interference on metastatic characters of human salivary adenoid cystic carcinoma.

Authors:  Hong Shi; Jie Wang; Fusheng Dong; Xu Wang; Hexiang Li; Yali Hou
Journal:  BMC Cancer       Date:  2009-12-21       Impact factor: 4.430

4.  Lipopolysaccharide can trigger a cathepsin B-dependent programmed death response in human endothelial cells.

Authors:  Jie H Li; Alessio D'Alessio; Jordan S Pober
Journal:  Am J Pathol       Date:  2009-08-06       Impact factor: 4.307

5.  Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice.

Authors:  Phong Trang; Jason F Wiggins; Christopher L Daige; Chris Cho; Michael Omotola; David Brown; Joanne B Weidhaas; Andreas G Bader; Frank J Slack
Journal:  Mol Ther       Date:  2011-03-22       Impact factor: 11.454

Review 6.  Brain delivery of small interfering ribonucleic acid and drugs through intranasal administration with nano-sized polymer micelles.

Authors:  Takanori Kanazawa
Journal:  Med Devices (Auckl)       Date:  2015-01-06

7.  MiR-382 functions as tumor suppressor and chemosensitizer in colorectal cancer.

Authors:  Hui Yao; Dong Xia; Zong-Lin Li; Lei Ren; Ming-Ming Wang; Wang-Sheng Chen; Zheng-Chuan Hu; Guo-Ping Yi; Liang Xu
Journal:  Biosci Rep       Date:  2019-08-09       Impact factor: 3.840

Review 8.  Delivery of RNAi mediators.

Authors:  Lance P Ford; Masoud M Toloue
Journal:  Wiley Interdiscip Rev RNA       Date:  2010-06-03       Impact factor: 9.957

Review 9.  RNA and disease.

Authors:  Thomas A Cooper; Lili Wan; Gideon Dreyfuss
Journal:  Cell       Date:  2009-02-20       Impact factor: 41.582

Review 10.  Current status of miRNA-targeting therapeutics and preclinical studies against gastroenterological carcinoma.

Authors:  Chikako Shibata; Motoyuki Otsuka; Takahiro Kishikawa; Takeshi Yoshikawa; Motoko Ohno; Akemi Takata; Kazuhiko Koike
Journal:  Mol Cell Ther       Date:  2013-12-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.